Cost-effectiveness and health outcomes of increased monitoring of adults with HBeAg-negative inactive CHB and HBeAg-positive immune tolerant CHB to 90% and increased antiviral treatment to 80% when they become treatment eligible compared to current practice for a population of 100,000 adults with inactive or immune tolerant CHB.
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://figshare.com/articles/dataset/Cost-effectiveness_and_health_outcomes_of_increased_monitoring_of_adults_with_HBeAg-negative_inactive_CHB_and_HBeAg-positive_immune_tolerant_CHB_to_90_and_increased_antiviral_treatment_to_80_when_they_become_treatment_eligible_compared_to_c/28256655
下载链接
链接失效反馈官方服务：
资源简介：
Cost-effectiveness and health outcomes of increased monitoring of adults with HBeAg-negative inactive CHB and HBeAg-positive immune tolerant CHB to 90% and increased antiviral treatment to 80% when they become treatment eligible compared to current practice for a population of 100,000 adults with inactive or immune tolerant CHB.
创建时间：
2025-01-22
